Kidney Disease
Research Study
Researchers at the University of North Carolina at Chapel Hill are examining the safety and effectiveness of an investigational medication for chronic kidney disease. Join our study today!
Fast Facts
history of kidney disease or reduced kidney function
No history of Diabetes
ages 10-65
compensation provided
conducted remotely (telephone visit) oR home health visit + visits in Chapel Hill, NC
Study Background
Researchers at the University of North Carolina at Chapel Hill (UNC) are taking part in the AMPLITUDE study sponsored by Vertex Pharmaceuticals Incorporated to investigate a potential treatment for APOL1-Mediated Chronic Kidney Disease.
While patients with APOL1-mediated kidney disease receive generalized therapies for their kidney disease, there are currently no approved treatments that address the underlying cause. As APOL1-mediated kidney disease has a genetic risk factor, it can affect multiple people in the same family and be passed down to younger generations. This is why clinical research is so important: to try to find a potential treatment that addresses the underlying cause and potentially help create better treatments for those impacted by the disease, now and for younger generations.
If you meet the requirements and choose to take part in the study, you will be given a full schedule with details about each study appointment. On the days when you have a scheduled appointment, you will either visit the study site, have a home health-service provider visit you, or have a mobile health visit. There will be more appointments in the first few weeks as you begin the study. After that, on average, you will have an appointment scheduled about every 8 weeks.
Further research today and join our compensated study!
Study Background
Researchers at the University of North Carolina at Chapel Hill (UNC) are taking part in the AMPLITUDE study sponsored by Vertex Pharmaceuticals Incorporated to investigate a potential treatment for APOL1-Mediated Chronic Kidney Disease.
While patients with APOL1-mediated kidney disease receive generalized therapies for their kidney disease, there are currently no approved treatments that address the underlying cause. As APOL1-mediated kidney disease has a genetic risk factor, it can affect multiple people in the same family and be passed down to younger generations. This is why clinical research is so important: to try to find a potential treatment that addresses the underlying cause and potentially help create better treatments for those impacted by the disease, now and for younger generations.
If you meet the requirements and choose to take part in the study, you will be given a full schedule with details about each study appointment. On the days when you have a scheduled appointment, you will either visit the study site, have a home health-service provider visit you, or have a mobile health visit. There will be more appointments in the first few weeks as you begin the study. After that, on average, you will have an appointment scheduled about every 8 weeks.
Further research today and join our compensated study!
Additional Information
This study is being done to learn more about the safety and effectiveness of the investigational drug VX-147 in participants with APOL1-Mediated Chronic Kidney Disease.
Several thousand years ago, the APOL1 variant genes evolved in people who lived in Western and Central Africa, to protect them from a parasitic disease known as African sleeping sickness.
Today, people of African descent across the globe may carry these APOL1 variants.
Researchers have learned that variants of the APOL1 gene are more likely to occur in people of African descent, which may include but is not limited to, people who identify as African American, Black, Caribbean, African, and/or Latino (Cuban, Mexican, Puerto Rican, or South or Central American).
You or your child may qualify for this study if you meet the following criteria.
Key Criteria:
- Ages 10-65
- History of kidney disease or reduced kidney function
- No diagnosis of cancer (other than skin or cervical cancer)
- No history of diabetes
- No diagnosis of Hepatitis B, C, or HIV
Once enrolled, this study involves:
- Participating in screening tests to determine eligibility
- Completing assessments
- May include questionnaires, physical exams, heart assessments, blood/urine samples, pregnancy tests
- Receiving the investigational drug or placebo at scheduled study visits
- Attending follow-up study visits
- Every 2 weeks for the first 3 visits
- Followed by every 4 weeks until week 48 (12 additional visits)
- Then every 8 weeks until the study ends
- Many/most of the visits are remote (telephone) or can be done by home health visits
Participants may be compensated for your study-related time and reimbursed
for expenses needed to participate in the clinical research study, like
transportation and meals. You will be given full details as to how much
you may be reimbursed by a member of the study team.
There is no cost for you or your child to participate in this study.